Id: | acc3029 |
Group: | 2sens |
Protein: | STAT5 |
Gene Symbol: | STAT5 |
Protein Id: | P42229 |
Protein Name: | STA5A_HUMAN |
PTM: | phosphorylation |
Site: | Tyr694 |
Site Sequence: | PVLAKAVDGYVKPQIKQVVPE |
Disease Category: | Cancer |
Disease: | Melanoma |
Disease Subtype: | |
Disease Cellline: | LU1205 |
Disease Info: | |
Drug: | PD98059 + LY294002 |
Drug Info: | PD98059 is a chemical compound used in biological research. | LY294002 is a commonly used inhibitor in scientific studies. |
Effect: | modulate |
Effect Info: | "After using the MEK–ERK inhibitor PD98059 and the PI3K inhibitor LY294002, the GAS–Luc activity of LU1205 cells was significantly increased, and the tyrosine phosphorylation of STAT3/5 and JAK2 was enhanced, indicating that the MAPK and PI3K signaling pathways inhibited the phosphorylation of JAK/STAT." |
Note: | drug comb |
Score: | 4.0 |
Pubmed(PMID): | 12821943 |
Sentence Index: | 12821943_5-6 |
Sentence: | "Tyrosine phosphorylation of STAT3/5 and of JAK2 also increased upon treatment of LU1205 cells with either PD or LY, suggesting that constitutive active MAPK and PI3K signals inhibit tyrosine phosphorylation of JAK/STATs. Treatment of FEMX and LU1205 with PD sensitized the cells to apoptosis, albeit by TNFalpha and TRAIL death cascades, respectively, indicating that additional yet distinct targets are affected by each signaling pathway." |
Sequence & Structure:
MAGWIQAQQLQGDALRQMQVLYGQHFPIEVRHYLAQWIESQPWDAIDLDNPQDRAQATQLLEGLVQELQKKAEHQVGEDGFLLKIKLGHYATQLQKTYDRCPLELVRCIRHILYNEQRLVREANNCSSPAGILVDAMSQKHLQINQTFEELRLVTQDTENELKKLQQTQEYFIIQYQESLRIQAQFAQLAQLSPQERLSRETALQQKQVSLEAWLQREAQTLQQYRVELAEKHQKTLQLLRKQQTIILDDELIQWKRRQQLAGNGGPPEGSLDVLQSWCEKLAEIIWQNRQQIRRAEHLCQQLPIPGPVEEMLAEVNATITDIISALVTSTFIIEKQPPQVLKTQTKFAATVRLLVGGKLNVHMNPPQVKATIISEQQAKSLLKNENTRNECSGEILNNCCVMEYHQATGTLSAHFRNMSLKRIKRADRRGAESVTEEKFTVLFESQFSVGSNELVFQVKTLSLPVVVIVHGSQDHNATATVLWDNAFAEPGRVPFAVPDKVLWPQLCEALNMKFKAEVQSNRGLTKENLVFLAQKLFNNSSSHLEDYSGLSVSWSQFNRENLPGWNYTFWQWFDGVMEVLKKHHKPHWNDGAILGFVNKQQAHDLLINKPDGTFLLRFSDSEIGGITIAWKFDSPERNLWNLKPFTTRDFSIRSLADRLGDLSYLIYVFPDRPKDEVFSKYYTPVLAKAVDGYVKPQIKQVVPEFVNASADAGGSSATYMDQAPSPAVCPQAPYNMYPQNPDHVLDQDGEFDLDETMDVARHVEELLRRPMDSLDSRLSPPAGLFTSARGSLS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
STAT5A-Ser128 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | -0.707 |
HGSC | 0.707 |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
STAT5A-Ser193 | |
---|---|
Cancer | Intensity |
BRCA | 1.009 |
COAD | 0.857 |
HGSC | |
ccRCC | -1.072 |
GBM | |
HNSC | -0.133 |
LUAD | -0.416 |
LUSC | 0.699 |
non_ccRCC | -1.956 |
PDAC | 0.705 |
UCEC | 0.307 |
STAT5A-Ser777 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | -1.133 |
GBM | |
HNSC | 0.761 |
LUAD | 0.372 |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
STAT5A-Ser780 | |
---|---|
Cancer | Intensity |
BRCA | 0.009 |
COAD | 0.02 |
HGSC | 1.43 |
ccRCC | -0.433 |
GBM | 2.195 |
HNSC | -0.072 |
LUAD | -0.075 |
LUSC | -0.269 |
non_ccRCC | -0.599 |
PDAC | -0.913 |
UCEC | -1.294 |
STAT5A-Tyr694 | |
---|---|
Cancer | Intensity |
BRCA | -0.21 |
COAD | 0.081 |
HGSC | 2.396 |
ccRCC | 0.242 |
GBM | -0.214 |
HNSC | 0.119 |
LUAD | 0.595 |
LUSC | 0.038 |
non_ccRCC | -1.223 |
PDAC | -0.376 |
UCEC | -1.449 |
STAT5B-Ser128 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | 0.523 |
HGSC | -1.153 |
ccRCC | 0.63 |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
STAT5B-Ser193 | |
---|---|
Cancer | Intensity |
BRCA | -0.438 |
COAD | -0.511 |
HGSC | 0.003 |
ccRCC | -1.881 |
GBM | 0.603 |
HNSC | 1.089 |
LUAD | -0.275 |
LUSC | 1.849 |
non_ccRCC | -0.664 |
PDAC | 0.612 |
UCEC | -0.387 |
STAT5B-Tyr699 | |
---|---|
Cancer | Intensity |
BRCA | -0.21 |
COAD | 0.081 |
HGSC | 2.396 |
ccRCC | 0.242 |
GBM | -0.214 |
HNSC | 0.119 |
LUAD | 0.595 |
LUSC | 0.038 |
non_ccRCC | -1.223 |
PDAC | -0.376 |
UCEC | -1.449 |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.